GlassScriptPhysician profile
Babafemi Pratt
NPI 1174773873
$87,431.60
in general payments reported to CMS, 2019-2025
27 companies · $946 in 2025
The $946 reported for 2025 was less than what a typical Vascular Surgery provider received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,470 · 2020: $173 · 2021: $7,463 · 2022: $56K · 2023: $19K · 2024: $802 · 2025: $946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $16K · Food and Beverage: $2,881 · Consulting Fee: $1,600 · Travel and Lodging: $806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $15,666.66 |
| Food and Beverage | $2,881.03 |
| Consulting Fee | $1,600.00 |
| Travel and Lodging | $806.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $77,853.13 | 2021-2023 | Auryon Laser System 100-120 Vac, Auryon Laser System 100-120 Vac |
| Boston Scientific Corporation | $4,036.91 | 2019-2025 | Peripheral Rotalink Plus, Eluvia, Coyote Es |
| Veryan Medical Incorporated | $1,421.23 | 2021-2024 | Biomimics 3d Vascular Stent System |
| Medtronic, INC. | $1,035.62 | 2021-2025 | Hawkone, Venaseal, In.Pact Admiral |
| Cardiovascular Systems INC. | $868.10 | 2019-2022 | |
| Abbott Laboratories | $603.90 | 2019-2025 | Esprit, Perclose Proglide, Diamondback Peripheral |
| W. L. Gore & Associates, INC. | $350.92 | 2019 | |
| Becton, Dickinson and Company | $178.31 | 2025 | Rotarexs 6 F X 135 Cm |
| Bolton Medical INC | $140.74 | 2024 | Treo Abdominal Stent-Graft System |
| Globus Medical, INC. | $134.22 | 2025 | Senza |
| Surmodics, INC. | $126.81 | 2023-2024 | Pounce Venous Thrombectomy System, Pounce Thrombectomy System, Pounce Thrombectomy |
| Nevro Corp. | $117.53 | 2024 | Senza |
| Janssen Pharmaceuticals, INC | $109.28 | 2021-2022 | |
| Csl Behring | $85.14 | 2019-2023 | Kcentra |
| Tactile Systems Technology INC | $78.26 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lemaitre Vascular, INC. | $60.90 | 2019 | |
| Asahi Intecc USA, INC. | $29.77 | 2021 | |
| Terumo Medical Corporation | $29.58 | 2021 | |
| Kerecis Limited | $25.71 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Avinger INC. | $23.73 | 2021 | |
| Philips North America LLC | $23.10 | 2023 | |
| Silk Road Medical, INC. | $19.33 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Biotronik INC. | $18.42 | 2022 | |
| Ekos Corporation | $17.39 | 2019 | |
| Ethicon US, LLC | $16.66 | 2019 | |
| Bard Peripheral Vascular, INC. | $14.86 | 2024 | Venovo |
| Integra Lifesciences Corporation | $12.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Babafemi Pratt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.